ioneering studies have revealed the presence of endogenous microRNAs (miRNAs) in the circulation that are not cell-associated. 1 The cellular origin and the biological function of circulating miRNAs, however, are less clear. 
On the basis of our recent finding that circulating miRNAs may reflect platelet activation, we further investigate the platelet contribution to circulating miRNAs. We provide proof-ofconcept for the potential of platelet miRNAs as a surrogate marker of efficacy of antiplatelet therapy.
Methods
An expanded Methods section is available in the Online Data Supplement.
Study Subjects
The following samples were obtained: (1) platelets, PMPs, serum, platelet-rich plasma, and platelet-poor (PPP) plasma were isolated from healthy volunteers (n=3) 6 ; (2) serum and PPP were collected from patients with type II diabetes mellitus (n=19, Online Table I ); (3) PPP was collected from healthy young men (<40 years, n=9) participating in a dose-escalation study of dual antiplatelet therapy at 4 timepoints 7 ; (4) validation was performed in PPP of patients with symptomatic carotid atherosclerosis 8 (n=33, Online Table II) .
Real-Time Polymerase Chain Reaction
MiRNAs were measured as described previously. 3, 4 The layout of custom-made quantitative polymerase chain reaction (qPCR) plates is shown in Online 
Results

Platelet Contribution to Circulating miRNAs
TaqMan miRNA fluidic cards (Human Pool Cards A v2.1) were used to assess a total of 377 miRNAs in platelets, PMPs, serum, platelet-rich plasma, and PPP of healthy individuals. Consistent with the expression data from platelets and PMPs (Online Figure I) , miR-223 was the most differentially expressed miRNA in platelet-rich plasma (Figure 1) . Similarly, when a panel of 28 miRNAs was compared in PPP and serum of diabetic patients (n=19), miR-223 showed the highest degree of classification potential (Figure 2A ). On examination of the minimum miRNA signature that could discriminate serum from PPP, circulating levels of miR-223 provided the best efficiency of prediction ( Figure 2B ). Other miRNAs present in platelets, such as miR-24, miR-191, and miR-197, had less efficient prediction accuracy.
Pharmacological Intervention in Healthy Volunteers
Given the lack of a gold standard for assessing platelet function, we explored the potential of platelet miRNAs as a surrogate marker of efficacy of antiplatelet therapy. Healthy young men (<40 years, n=9) were given 10 mg prasugrel (week 1), followed by a combination therapy with low-dose aspirin (75 mg, week 2) and higher-dose aspirin (300 mg, week 3). This dose escalation of aspirin in combination with prasugrel resulted in increasing platelet inhibition. As reported previously, 7 platelet function was assessed by 96-well plate aggregometry and the formation of thromboxane A 2 (measured as thromboxane B 2 ) by clotting blood, with response to treatment being additionally assessed by VerifyNow, and urine samples being retained for quantification of prostanoid metabolites on days 0, 7, 14, and 21 (Online Figure II) . Using custom-designed qPCR plates preplated by the TaqMan custom plating service, 92 miRNAs were tested in PPP of a subset of 6 individuals. An exogenous spike-in control (Caenorhabditis elegans miRNA celmiR-39) was used for normalization. Significant differences were identified for 15 miRNAs over the 4 time points (Online Figure III) . To confirm the effect of dual antiplatelet therapy, selected miRNAs were quantified in all participants by individual TaqMan qPCR assays (Figure 3 ). Correlation coefficients with custom-made qPCR plates were >0.9. Notably, U6, a noncoding RNA frequently used for normalization, was affected by antiplatelet medication at week 1 and week 2 (P<0.05 in paired t test).
Pharmacological Intervention in Patients
Findings in healthy volunteers were corroborated by miRNA measurements in patients with recently symptomatic carotid atherosclerosis (n=33, Online Table II ) participating in a randomized trial to determine whether treatment with dipyridamole or clopidogrel, in addition to aspirin, was more effective at reducing embolization. 8 Both treatment regimens had similar efficacy in reducing embolization, as evaluated using transcranial Doppler detection of cerebral embolic signals. 8 Twelve patients were randomly selected for miRNA analysis. All patients were on 75 mg of aspirin at baseline. Eight were randomized and received dipyridamole and 4 clopidogrel in February 15, 2013 addition to aspirin. After 48 hours, effects on miRNAs were assessed in PPP using custom-designed miRNA qPCR plates based on Exiqon's locked nucleic acid technology to further ensure robustness of data independent of the technological platform (Online Figure IV) . Selected miRNAs were quantified in all patients (n=33) by individual TaqMan qPCR assays ( Figure 4) . As in healthy volunteers, more potent platelet inhibition resulted in a reduction of miR-126 (P<0.001), miR-150 (P=0.003), miR-191 (P=0.004), and miR-223 (P=0.016), providing independent confirmation of our findings in a patient cohort, who were not naive for antiplatelet agents. In comparison, changes in ex vivo measurements of peak aggregation to ADP and collagen were less pronounced (Online Table II ).
Discussion
The present study identified circulating platelet miRNAs that are responsive to antiplatelet therapy. Particular strengths of our study are as follows: (1) the repeated measurements in healthy individuals; (2) the additional investigation in patients on dual antiplatelet therapy; (3) the large number of miRNAs that were assessed by using custom-designed miRNA qPCR plates based on 2 different technologies (locked nucleic acid and TaqMan). 
Circulating Platelet miRNAs
Platelets represent the second most abundant cell type in blood. Although their miRNA content is low compared with other cells, platelets contribute substantially to the circulating miR-NA pool. Any inconsistencies in plasma preparation will have profound effects on the miRNA content. Also, platelets shed microparticles on activation. Reduced microparticle shedding on platelet inhibition is likely to be responsible for the observed decrease in plasma miRNAs. Antiplatelet therapy was probably a confounding factor in previous case-control studies Figure IV) , a panel of 8 miRNAs plus U6 was assessed in patients with symptomatic carotid atherosclerosis (n=33) who were on 75 mg aspirin (ASA) at baseline. Samples were taken 48 h after initiation of dual antiplatelet therapy with either dipyridamole or clopidogrel. *Groups depicted in red differ significantly in their average ΔCt value from the baseline group (tested by paired t tests, critical probability value of 0.05).
reporting a loss of miRNAs in patients with coronary artery disease. 10 Similarly, the transcoronary concentration gradients of noncardiac miRNAs may be related to platelet adhesion in the coronary circulation. 11 Given our limited knowledge about circulating miRNAs, 12 well-controlled intervention studies are needed to fill the significant gaps in our current knowledge about the effects of medication on circulating miRNAs.
Effects of Antiplatelet Therapy
Antiplatelet therapy plays a prime role in treatment and prevention of myocardial infarction and strokes. Yet, there is still no widely agreed and ideal measure of platelet activation to assess antiplatelet efficacy. 13 Importantly, the combination therapy of aspirin plus P2Y 12 inhibitors is associated with a significant bleeding risk, which can be lifethreatening in a small but significant number of patients. 14 Combination therapy is commonly used for the management of non-ST-elevation acute coronary syndromes and ST-elevation myocardial infarction. Aspirin inhibits the production of thromboxanes. P2Y 12 inhibitors, such as clopidogrel, prasugrel, and ticagrelor, act by inhibiting ADP receptors. Thus, their mechanisms are complementary but variability in response to clopidogrel has been associated with gastrointestinal absorption, drug interactions, and P450 isoenzyme activity. 15 There is currently no one measure or standard definition in tests for antiplatelet efficacy. 13 Our study provides evidence that platelet miRNAs should be explored as a point-of-care test for tailoring antiplatelet therapies. These findings could become even more important as new potent antiplatelet agents are currently developed and tested in clinical trials.
Clinical Implications
miRNAs are stable and readily determined by qPCR, a technique widely used for viral diagnostics in clinical laboratories. Furthermore, quantification of miRNAs may well provide information about platelet reactivity within the circulation, which is a result of a balance between pro-and antiaggregatory stimuli. Tests of platelet reactivity to date have concentrated on assessing platelet responses ex vivo. Such approaches have notably failed to provide any useful guidance to antiplatelet medication. Thus, a clinical introduction of platelet miRNA assays could address the need to provide tailored effective antiplatelet therapy. Future studies will need to explore whether platelet miRNA-guided dosing of therapy can improve therapeutic outcomes.
Conclusions
Repeated measurements in healthy volunteers and patients on antiplatelet therapy provided proof-of-concept that miRNAs could serve as novel biomarkers of platelet activation and codiagnostic for efficacy of antiplatelet therapy. This awaits confirmation in larger studies. Our findings also highlight that antiplatelet therapy is a potential confounding factor for miRNA measurements in case-control studies of cardiovascular disease.
